Stakeholder Groups

B1MG Stakeholder Portal

Patient Organisations

Three disease areas organise this cluster: oncology, rare disease and neurology. Each area will have a lead to tackle disease‐specific questions.

Clinicians and medical specialists

This cluster comprises two subgroups, clinicians and medical specialists, from the oncology, rare disease and neurology areas.

HTA bodies

Health technology assessment (HTA) refers to the systematic evaluation of properties, effects, and the impact of health technology. This multidisciplinary process evaluates the social, economic, organisational and ethical issues of a health intervention or technology.

A EUnetHTA representative will lead this cluster.

Medicines Authorities

EU/EMA and national level:

  • EMA

  • BfArM

  • AEMPS

  • European Medicines Agency

  • Swedish Medical Products Agency

  • MHRA

  • AIFA

  • SwissMedic

Academics

This cluster includes academics and researchers involved in oncology, rare disease, neurology and data science.

Industry

Group of experts from industry companies, such as diagnostic, pharmaceutical and ICT

National Policy and decision makers

This cluster involves decision-making individuals that sign policy documents or allocate funds at the national level. This group connects key national policy/decision-makers with the relevant B1MG policy area.

Funders

The group concerns any decision‐makers that are involved in setting therapies and reimbursed price or deciding regional/hospital healthcare budget allocation.

Research Infrastructures

This group comprises the facilities that foster innovation and provide resources and services for research communities to conduct research. These can go beyond research (e.g. education, public services) and they may be single-sited, distributed, or virtual.

EU Joint Actions

Joint Actions are a type of funding instrument under the third EU Health Programme. They encourage and support cooperation between the Member States to improve the health policies that benefit their citizens.

This group will include actions in the area of cancer and rare diseases.